Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952155 | 0.80 | CYP4F2 (0.56) | CYP4F2CYP4A11NPSR1LMNAP2RX7 | |
| SCHEMBL17535 | 0.80 | CYP4F2 (0.52) | CYP4F2CYP4A11NPSR1LMNAP2RX7 | |
| SCHEMBL11474888 | 0.79 | CYP4F2 (0.65) | CYP4F2CYP4A11NPSR1 | |
| SCHEMBL1203976 | 0.78 | CYP4F2 (0.50) | CYP4F2CYP4A11NPSR1LMNAP2RX7 | |
| SCHEMBL15572190 | 0.78 | CYP4F2 (0.50) | CYP4F2CYP4A11NPSR1LMNAP2RX7 | |
| SCHEMBL26988704 | 0.78 | CYP4F2 (0.50) | CYP4F2CYP4A11NPSR1LMNAP2RX7 | |
| SCHEMBL8393649 | 0.78 | CYP4F2 (0.50) | CYP4F2CYP4A11NPSR1LMNAP2RX7 | |
| Hydrochloric Acid SCHEMBL22034867 | 0.77 | CYP4F2 (0.49) | CYP4F2CYP4A11NPSR1LMNAP2RX7 | |
| SCHEMBL5271625 | 0.77 | CYP4F2 (0.58) | CYP4F2CYP4A11NPSR1LMNAP2RX7 | |
| SCHEMBL761603 | 0.76 | CYP4F2 (0.61) | CYP4F2CYP4A11NPSR1LMNAP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212180-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212180-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | PTPN5, PTPN1, PTPN2 | CYP4F2 1104/4885CYP4A11 288/4885NPSR1 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.